The Gross Law Firm Notifies AstraZeneca PLC Investors of a Class Action Lawsuit and Upcoming Deadline - AZN

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of AstraZeneca PLC regarding a class action lawsuit alleging that the company engaged in insurance fraud in China, leading to legal exposure and potential harm to its business activities in the region [1]. Group 1: Allegations and Legal Context - The class period for the allegations is from February 23, 2022, to December 17, 2024 [1]. - Allegations include that AstraZeneca issued materially false and misleading statements and failed to disclose its involvement in insurance fraud in China [1]. - The lawsuit claims that the legal exposure faced by AstraZeneca in China resulted in the detention of the AstraZeneca China President by law enforcement [1]. - It is asserted that AstraZeneca understated its legal risks, which could materially harm its business activities in China once revealed [1]. Group 2: Shareholder Actions and Deadlines - Shareholders who purchased shares of AZN during the specified class period are encouraged to register for the class action [2]. - The deadline for shareholders to seek lead plaintiff status is February 21, 2025 [2]. - Registered shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle [2]. Group 3: Firm's Mission and Commitment - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and engage in good corporate citizenship [3].